Plan B status
This article was originally published in The Tan Sheet
Barr Labs expects to receive an "approvable" letter from FDA before a Feb. 20 PDUFA deadline for switching its emergency contraceptive pill Plan B (levonorgestrel .75 mg) from prescription to over-the-counter status. During a Feb. 5 earnings call, execs confirmed Barr's R&D group has met recently with the agency regarding the switch application. The Pomona, N.Y.-based firm also maintains the product will be successful for Barr even if it stays an Rx drug. Barr expects to complete the purchase of Plan B developer Women's Capital Corp. within the next two weeks; the firm signed a letter of intent to purchase WCC in October 2003 (1"The Tan Sheet" Oct. 6, 2003, p. 3)...
You may also be interested in...
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.